Drug Profile
ABT 301
Alternative Names: ABT-301; MPT-0E028Latest Information Update: 03 Aug 2023
Price :
$50
*
At a glance
- Originator Formosa Pharmaceuticals; Taipei Medical University
- Developer AnBogen Therapeutics; Formosa Pharmaceuticals; Taipei Medical University
- Class Antineoplastics; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 03 Aug 2023 Chemical structure information added
- 07 Jul 2023 ABT 301 regionally licensed to Anbogen Therapeutics (Taiwan) (Formosa Pharmaceuticals pipeline, July 2023)
- 07 Jul 2023 AnBogen Therapeutics plans a phase II trial for Hodgkin's-disease in 2025 (AnBogen Therapeutics pipeline, July 2023)